Meta AnalysisID 7242
直接口服抗凝药和低分子肝素对泌尿外科手术患者的影响：网状Meta分析和累积Meta分析
CRD42023487949
What is the impact of direct oral anticoagulants or low molecular weight heparin on the surgical outcomes of patients undergoing urological surgery?
Relationship Network
Interactive first-hop connections across herbs, ingredients, formulas, targets, diseases, symptoms, syndromes, evidence, and monographs.
Click a node to open it in a new tab
Ingredient: 1Meta-analysis: 1Links: 1
Arranging relationship network...
Record Fields
Scalar fields from the final meta_analysis record.
- Meta Analysis Id
- 7242
- Evidence Id
- 15800
- Core Evidence Id
- 15800
- Source Meta Analysis Id
- 7277
- Herb2 Meta Analysis Id
- HBMA007277
- Crd Id
- CRD42023487949
- Title
- The impact of direct oral anticoagulants and low molecular weight heparin on urological surgery patients: a network meta-analysis and cumulative meta-analysis
- Review Question
- What is the impact of direct oral anticoagulants or low molecular weight heparin on the surgical outcomes of patients undergoing urological surgery?
- Study Type Included
- Cohort studies. Randomized controlled trial
- Condition Being Studied
- Venous thrombosis. Urological surgery. Oral anticoagulants. Low molecular weight heparin.
- Participant
- Inclusion: Urology surgery patients. (Preoperative use of oral anticoagulants or low molecular weight heparin for anticoagulation) Exclusion: Patients undergoing non-urological surgeries, such as cardiac surgery or vascular surgery. Urology surgery patients. (Anticoagulation with medications other than oral anticoagulants or low molecular weight heparin before surgery).
- Animal
- Human Disease Modelled
- Intervention
- DOACs stands for Direct Oral Anticoagulants. These are a class of anticoagulant medications that are administered orally. Unlike traditional anticoagulants such as warfarin, DOACs directly target specific clotting factors, providing a more direct and predictable effect. The main types of DOACs include: Dabigatran (Pradaxa): Inhibits thrombin (Factor IIa). Rivaroxaban (Xarelto): Inhibits Factor Xa. Apixaban (Eliquis): Also inhibits Factor Xa. Edoxaban (Savaysa): Another Factor Xa inhibitor. Low molecular weight heparin (LMWH) is a type of anticoagulant medication that is derived from unfractionated heparin (UFH). Heparin is a naturally occurring substance found in the body, and it works by enhancing the activity of antithrombin III, a natural anticoagulant. LMWH is produced by breaking down heparin into smaller fragments, resulting in molecules with a lower molecular weight.
- Comparator Control
- Comparison between urological surgery patients taking direct oral anticoagulants and those taking oral low molecular weight heparin.
- Main Outcome
- Venous thrombosis. Pulmonary embolism. Heavy bleeding Measures of effect odds ratios
- Outcome Measure
- Additional Outcome
- Study Method
- Epidemiologic, Meta-analysis, Systematic review
- Keyword
- MeSH headings have not been applied to this record
- Contact
- hao xuexue [email protected]
- Organisational Affiliation
- Tianjin Medical University http://www.tmu.edu.cn/
- Funding Source
- Tianjin Medical University General Hospital
- Other Selection Criteria
- Final Publication
- Same Topic Review
- Published Protocol
- Review Type
- Language
- English
- Country
- China
- Review Stage
- Review Ongoing
- First Submission Date
- 2023-11-29
- Registration Date
- 2023-12-12
- Anticipated Start Date
- 2023-11-25
- Anticipated Completion Date
- 2024-01-01
- Title Cn
- 直接口服抗凝药和低分子肝素对泌尿外科手术患者的影响：网状Meta分析和累积Meta分析
- Title En
- The impact of direct oral anticoagulants and low molecular weight heparin on urological surgery patients: a network meta-analysis and cumulative meta-analysis
- Bilingual Status
- complete